Guide to designing, conducting, publishing and communicating results of clinical studies involving probiotic applications in human participants

Gut Microbes

Volumn 1, Issue 4, 2010, Pages 243-253

  Shane, Andi L ^a   Cabana, Michael D ^b   Vidry, Stéphane ^c   Merenstein, Dan ^d   Hummelen, Ruben ^e   Ellis, Collin L ^f   Heimbach, James T ^g   Hempel, Susanne ^h   Lynch, Susan V ⁱ   Sanders, Mary Ellen ^e   Tancredi, Daniel J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b International Life Sciences Institute of Europe   (Belgium)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f JHeimbach LLC   (United States)

^g RAND CORPORATION   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ DAIRY AND FOOD CULTURE TECHNOLOGIES   (United States)

Author keywords

Clinical trials; Guidelines; Human; Probiotics; Study design

Indexed keywords

EID: 79251480110     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: 10.4161/gmic.1.4.12707     Document Type: Review

References (80)

1. Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chicester, UK: John Wiley & Sons, Ltd 2006.
2. European Medicines Agency E. General Considerations for Clincial Trials. ICH Topic E8 1998.
3. European Medicines Agency E. Notice for Guidance on Choice of Control Group in Clinical Trials. ICH Topic E 10. London 2001.
4. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53:1617-23.
5. Ebell M, JS, Weiss B, Woolf S, Susman J, Ewigman B, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician 2004; 69:548-56.
6. FDA. Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims-Final. In: Nutrition CfFSaA, ed., 2009.
7. FAO WHO. Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live lactic Acid Bacteria. Cordoba, Argentina: WHO/FAO 2001.
8. Moher D, Hopewell S, Schulz K, Montori V, Gøtzsche P, Devereaux P, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010; 63:e1-37.
9. Schulz K, Altman D, Moher D. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. PLoS Med 2010; 7.
10. Haynes R. Incorporating allocation concealment and blinding in randomised controlled trials. Evid Based Med 2000; 5:38.
11. Jüni P, Altman D, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001; 323:42-6.
12. Canada H. Guidance Document for Preparing a Submission for Food Health Claims. In: Bureau of Nutritional Sciences Food Directorate HPaFB, ed., 2009; Epub.
13. Ebell M, Siwek J, Weiss B, Woolf S, Susman J, Ewigman B, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract 2004; 17:59-67.
14. Nishitani Y, Tanoue T, Yamada K, Ishida T, Yoshida M, Azuma T, et al. Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice. Int Immunopharmacol 2009; 9:1444-51.
15. Prisciandaro L, Geier M, Butler R, Cummins A, Howarth G. Probiotics and their derivatives as treatments for inflammatory bowel disease. Inflamm Bowel Dis 2009; 15:1906-14.
16. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano R, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009; 104:437-43.
17. Llopis M, Antolin M, Carol M, Borruel N, Casellas F, Martinez C, et al. Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa. Inflamm Bowel Dis 2009; 15:275-83.
18. Maldonado J, Lara-Villoslada F, Sierra S, Sempere L, Gómez M, Rodriguez J, et al. Safety and tolerance of the human milk probiotic strain Lactobacillus salivarius CECT5713 in 6-month-old children. Nutrition 2009; Epub ahead of print.
19. Senok A, Verstraelen H, Temmerman M, Botta G. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev 2009; 006289.
20. Giamarellos-Bourboulis E, Bengmark S, Kanellakopoulou K, Kotzampassi K. Pro- and synbiotics to control inflammation and infection in patients with multiple injuries. J Trauma 2009; 67:815-21.
21. Coeuret V, Gueguen M, Vernoux J. Numbers and strains of lactobacilli in some probiotic products. Int J Food Microbiol 2004; 97:147-56.
22. Huys G, Vancanneyt M, D'Haene K, Vankerckhoven V, Goossens H, Swings J. Accuracy of species identity of commercial bacterial cultures intended for probiotic or nutritional use. Res Microbiol 2006; 157:803-10.
23. Drisko J, Bischoff B, Giles C, Adelson M, Rao R, McCallum R. Evaluation of five probiotic products for label claims by DNA extraction and polymerase chain reaction analysis. Dig Dis Sci 2005; 50:1113-7.
24. Turroni F, Marchesi J, Foroni E, Gueimonde M, Shanahan F, Margolles A, et al. Microbiomic analysis of the bifidobacterial population in the human distal gut. ISME J 2009; 3:745-51.
25. Zoetendal E, Rajilic-Stojanovic M, de Vos W. High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 2008; 57:1605-15.
26. Costello E, Lauber C, Hamady M, Fierer N, Gordon J, Knight R. Bacterial community variation in human body habitats across space and time. Science 2009; 326:1694-7.
27. Turnbaugh P, Gordon J. The core gut microbiome, energy balance and obesity. J Physiol 2009; 587:4153-8.
28. Baele M, Vaneechoutte M, Verhelst R, Vancanneyt M, Devriese L, Haesebrouck F. Identification of Lactobacillus species using tDNA-PCR. J Microbiol Methods 2002; 50:263-71.
29. Desai A, Shah N, Powell I. Discrimination of dairy industry isolates of the Lactobacillus casei group. J Dairy Sci 2006; 89:3345-51.
30. Vandamme P, Pot B, Gillis M, de Vos P, Kersters K, Swings J. Polyphasic taxonomy, a consensus approach to bacterial systematics. Microbiol Rev 1996; 60:407-38.
31. Gancheva A, Pot B, Vanhonacker K, Hoste B, Kersters K. A polyphasic approach towards the identification of strains belonging to Lactobacillus acidophilus and related species. Syst Appl Microbiol 1999; 22:573-85.
32. Huang C, Lee F, Liou J. Rapid discrimination and classification of the Lactobacillus plantarum group based on a partial dnaK sequence and DNA fingerprinting techniques. Antonie Van Leeuwenhoek 2010; 97:289-96.
33. Stephenson D, Moore R, Allison G. Comparison and utilization of repetitive-element PCR techniques for typing Lactobacillus isolates from the chicken gastrointestinal tract. Appl Environ Microbiol 2009; 75:6764-76.
34. Masco L, Huys G, Gevers D, Verbrugghen L, Swings J. Identification of Bifidobacterium species using rep-PCR fingerprinting. Syst Appl Microbiol 2003; 26:557-63.
35. Ahlroos T, Tynkkynen S. Quantitative strain-specific detection of Lactobacillus rhamnosus GG in human faecal samples by real-time PCR. J Appl Microbiol 2009; 106:506-14.
36. Weckx S, Allemeersch J, Van der Meulen R, Vrancken G, Huys G, Vandamme P, et al. Development and validation of a species-independent functional gene micro-array that targets lactic acid bacteria. Appl Environ Microbiol 2009; 75:6488-95.
37. Klaassens E, Boesten R, Haarman M, Knol J, Schuren F, Vaughan E, et al. Mixed-species genomic microar-ray analysis of fecal samples reveals differential tran-scriptional responses of bifidobacteria in breast- and formula-fed infants. Appl Environ Microbiol 2009; 75:2668-76.
38. González R, Klaassens E, Malinen E, de Vos W, Vaughan E. Differential transcriptional response of Bifidobacterium longum to human milk, formula milk and galactooligosaccharide. Appl Environ Microbiol 2008; 74:4686-94.
39. Weber D, Sahm K, Polen T, Wendisch V, Antranikian G. Oligonucleotide microarrays for the detection and identification of viable beer spoilage bacteria. J Appl Microbiol 2008; 105:951-62.
40. Sanders ME, Marco M. Food formats for effective delivery of probiotics. Ann Rev Food Sci Technol 2010; 1:65-85.
41. Saarela M, Virkajärvi I, Alakomi H, Mattila-Sandholm T, Vaari A, Suomalainen T, et al. Influence of fermentation time, cryoprotectant and neutralization of cell concentrate on freeze-drying survival, storage stability and acid and bile exposure of Bifidobacterium animalis ssp. lactis cells produced without milk-based ingredients. J Appl Microbiol 2005; 99:1330-9.
42. Saarela M, Alakomi H, Puhakka A, Mättö J. Effect of the fermentation pH on the storage stability of Lactobacillus rhamnosus preparations and suitability of in vitro analyses of cell physiological functions to predict it. J Appl Microbiol 2009; 106:1204-12.
43. Arribas B, Rodríguez-Cabezas M, Camuesco D, Comalada M, Bailón E, Utrilla P, et al. A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipo-polysaccharide-induced sepsis in mice. Br J Pharmacol 2009; 157:1024-33.
44. Selvam R, Maheswari P, Kavitha P, Ravichandran M, Sas B, Ramchand C. Effect of Bacillus subtilis PB6, a natural probiotic on colon mucosal inflammation and plasma cytokines levels in inflammatory bowel disease. Indian J Biochem Biophys 2009; 46:79-85.
45. Kokesová A, Frolová L, Kverka M, Sokol D, Rossmann P, Bártová J, et al. Oral administration of probiotic bacteria (E. coli Nissle E. coli O83, Lactobacillus casei) influences the severity of dextran sodium sul-fate-induced colitis in BALB/c mice. Folia Microbiol (Praha) 2006; 51:478-84.
46. Sleator R, Hill C. Improving probiotic function using a patho-biotechnology approach. Gene Ther Mol Biol 2007; 11:269-74.
47. Kim J, Kwon J, Ahn S, Lee S, Han Y, Choi Y, et al. Effect of probiotic mix (Bifidobacterium bifi-dum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial. Pediatr Allergy Immunol 2010; 21:e386-93.
48. Czaja C, Stapleton A, Yarova-Yarovaya Y, Stamm W. Phase I trial of a Lactobacillus crispatus vaginal suppository for prevention of recurrent urinary tract infection in women. Infect Dis Obstet Gynecol 2007; 2007:35387.
49. Uehara S, Monden K, Nomoto K, Seno Y, Kariyama R, Kumon H. A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. Int J Antimicrob Agents 2006; 28:30-4.
50. Kosaraju S. Colon targeted delivery systems: review of polysaccharides for encapsulation and delivery. Crit Rev Food Sci Nutr 2005; 45:251-8.
51. Barth S, Duncker S, Hempe J, Breves G, Baljer G, Bauerfeind R. Escherichia coli Nissle 1917 for probiotic use in piglets: evidence for intestinal colonization. J Appl Microbiol 2009; 107:1697-710.
52. Schultz M, Watzl S, Oelschlaeger T, Rath H, Göttl C, Lehn N, et al. Green fluorescent protein for detection of the probiotic microorganism Escherichia coli strain Nissle 1917 (EcN) in vivo. J Microbiol Methods 2005; 61:389-98.
53. Kleta S, Steinrück H, Breves G, Duncker S, Laturnus C, Wieler L, et al. Detection and distribution of probiotic Escherichia coli Nissle 1917 clones in swine herds in Germany. J Appl Microbiol 2006; 101:1357-66.
54. Weiss K, Siegel J. Issues in endpoint selection. In: Cato A, Suton L, Cato A, eds. Clinical Drug Trials and Tribulations. New York: Marcel Dekker Inc. 2002; 79-92.
55. Echt D, Liebson P, Mitchell L, Peters R, Obias-Manno D, Barker A, et al. Mortality and morbidity in patients receiving encainide, flecainide or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781-8.
56. Chin R, Lee B. Endpoints. Principals and Practice of Clinical Trial Medicine: Elsevier 1996; 121-44.
57. Grimes D, Schulz K. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol 2005; 105:1114-8.
58. Chuang-Stein C. Laboratory data in clinical trials: a a staistician's perspective. Controlled Clinical Trials 1998; 19:167-77.
59. Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R. Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ 2002; 324:1417.
60. Drossman D, Patrick D, Whitehead W, Toner B, Diamant N, Hu Y, et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000; 95:999-1007.
61. FDA. Guidance for Industry: Patient Reported Outcome Measurements, Use in Medical Product Development to Support Labeling Claims., 2006; http://wwwfdagov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282pdf.
62. Osterberg L, Blaschke T. Adherence to Medication. N Engl J Med 2005; 353:487-97.
63. Claxton A, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23:1296-310.
64. Gilbert J, Evans C, Haynes R, Tugwell P. Predicting compliance with a regimen of digoxin therapy in family practice. Can Med Assoc J 1980; 123:119-22.
65. Miller L, Hays R. Measuring adherence to antiretroviral medications in clinical trials. HIV Clin Trials 2000; 1:36-46.
66. McIntosh H, Woolacott N, Bagnall A. Assessing harmful effects in systematic reviews. BMC Med Res Methodol 2004; 4:19.
67. Ioannidis J, Evans S, Gøtzsche P, O'Neill R, Altman D, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004; 141:781-8.
68. National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE). In: Services United States Department of Health and Human Services, 2009.
69. Ioannidis J, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001; 285:437-43.
70. Altman D, Schulz K, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134:663-94.
71. AHRQ. Safety of Probiotics Used to Reduce Risk and Prevent or Treat Disease. Rockville: Agency for healthcare Research and Quality:http://www.ahrq.gov/clinic/tp/probiotictp.htm.
72. Chou R, Aronson N, Atkins D, Ismaila A, Santaguida P, Smith D, et al. Assessing harms when comparing medical interventions: AHRQ and the Effective Health-Care Program. J Clin Epidemiol 2010; 63:502-12.
73. European Food Safety Authority. Briefing document for Member States and European Commission on the evaluation of Article 13.1 health claims. Parma, Italy, 11 November 2009; EFSA Journal 2009; 7:1386.
74. Health Canada. Guidance Document-The Use of Probiotic Microorganisms in Food 2009, Food Directorate, Health Products and Food Branch, Health Canada, April 2009. Accessible via http://www.hc-sc.gc.ca/fn-an/alt_formats/hpfb-dgpsa/pdf/legislation/probiotics_guidance-orientation_probiotiques-eng.pdf.
75. Gokhale G, Nadkarni A. Probiotic foods market in India soon to be regulated. India Law Journal, 2007, Accessible via http://www.indialawjournal.com/vol-ume3/issue_1/article_by_aditi.html.
76. Sanders M, Tompkins T, Heimbach J, Kolida S. Weight of evidence needed to substantiate a health effect for probiotics and prebiotics: regulatory considerations in Canada EU and U.S. Eur J Nutr 2005; 44:303-10.
77. Sanders M, Hamilton J, Reid G, Gibson G. A nonvi-able preparation of Lactobacillus acidophilus is not a probiotic. Clin Infect Dis 2007; 44:886.
78. Pineiro M, Stanton C. Probiotic bacteria: legislative framework-requirements to evidence basis. J Nutr 2007; 137:850-3.
79. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 2004; 1:189-95.
80. FDA. Guidance for Industry: Substantiation for Dietary Supplement Claims Made Under Section 403 (r) (6) of the Federal Food, Drug and Cosmetic Act. In: Office of Nutrition L and Dietary Supplements, ed. 2008.